IGF-1 as feline vaccine adjuvant, in particular against feline retroviruses
US7326417B2 · kind B2 · utility
0Cited by
3References
22Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Sep 10, 2002 |
| Grant date | Feb 5, 2008 |
| Priority date | — |
| Expiry date | Mar 16, 2023 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/15034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to feline IGF-1, to the nucleotide sequence encoding this protein and to the use of IGF-1 as adjuvant for the vaccination of cats, in particular against the feline retroviruses FIV and FeLV. IGF-1 may be used in the form of protein or may be expressed in vivo by a suitable, e.g. viral or plasmid, expression vector. The invention relates to all types of vaccines, namely inactivated, attenuated, sub-unit and recombinant vaccines. The vectors expressing IGF-1 in vivo may also be used in immunity-stimulating compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.